Human Immunodeficiency Virus type 1 (HIV-1) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook

Thelansis’s “Human Immunodeficiency Virus type 1 (HIV-1) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Human Immunodeficiency Virus type 1 treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Human Immunodeficiency Virus type 1 (HIV-1) Overview

Human Immunodeficiency Virus type 1 (HIV-1) is a retrovirus that infects humans and is the primary cause of acquired immunodeficiency syndrome (AIDS). It belongs to the Lentivirus genus of the Retroviridae family. HIV-1 is one of the two major types of HIV, the other being HIV-2. HIV-1 is transmitted by exchanging body fluids, including blood, semen, vaginal fluids, rectal fluids, and breast milk. The most common transmission routes include unprotected sexual contact with an infected person, sharing needles or syringes with an infected person, and transmission from an infected mother to her child during childbirth or breastfeeding. Once the virus enters the body, it primarily targets and infects CD4+ T cells, a type of white blood cell crucial for the immune system's proper functioning. As the virus replicates, it progressively destroys these CD4+ T cells, weakening the immune system and making the person more susceptible to opportunistic infections and certain cancers. The course of HIV infection is divided into several stages:

1. Acute HIV infection: This occurs within a few weeks after the initial infection and may cause flu-like symptoms such as headache, fever, sore throat, swollen lymph nodes, and rash.
2. Clinical latency: After the initial stage, HIV remains in the body but may not cause noticeable symptoms for an extended period. However, the virus continues to replicate and damage the immune system during this time.
3. Acquired Immunodeficiency Syndrome (AIDS): If HIV is left untreated, the immune system becomes severely damaged, and the person is diagnosed with AIDS. At this stage, the individual becomes highly susceptible to opportunistic infections and certain cancers.

HIV can be managed effectively with antiretroviral therapy (ART), a combination of medications that helps suppress viral replication and maintain a healthy immune system. While ART does not cure HIV, it allows people living with the virus to lead relatively healthy lives and significantly reduces the risk of transmitting it to others.

• The estimated number of HIV infections in the USA was 12.6 per 100,000.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: